Scancell research collaboration deal with European biopharma BioNTech

Published on 12th Jan 2018

Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer. Scancell Co-Founder and Non-Executive Director Richard Goodfellow tells Proactive why the deal is significant for investors. The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors.

Pharma & Biotech
Add to favorites
Share with:

Related Videos

Latest

Recommended videos

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082.
You can contact us here.

Choose Proactive Region: